Insulet Co. (NASDAQ:PODD) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Insulet Co. (NASDAQ:PODD - Get Free Report) have received an average recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $272.81.

A number of research analysts recently issued reports on PODD shares. Canaccord Genuity Group lifted their target price on Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a report on Monday, December 9th. Morgan Stanley upped their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Raymond James boosted their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a report on Monday, October 14th. Piper Sandler raised their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Finally, TD Cowen lifted their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company's stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.47% of the stock is owned by insiders.

Hedge Funds Weigh In On Insulet

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. increased its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 58 shares in the last quarter. Venturi Wealth Management LLC increased its stake in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial purchased a new stake in Insulet during the fourth quarter worth $57,000. Finally, Versant Capital Management Inc grew its holdings in Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after purchasing an additional 157 shares during the last quarter.

Insulet Stock Down 1.4 %

Shares of PODD stock traded down $3.84 during trading on Monday, reaching $267.99. The company's stock had a trading volume of 453,430 shares, compared to its average volume of 487,133. The company has a market capitalization of $18.80 billion, a price-to-earnings ratio of 45.89, a P/E/G ratio of 4.12 and a beta of 1.22. Insulet has a 1-year low of $160.19 and a 1-year high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock's 50-day moving average price is $264.57 and its 200 day moving average price is $230.93.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.